hereditary hemorrhagic telangiectasia

But, um, yeah, despite being August, we actually had a pretty big week last week with at least 13 rounds, bringing in $791 million, and the biggest round of the week went to Videris, a Swiss company.

So they're not on holiday right now, and they have an oral allosteric AKT inhibitor for a rare disease, HHT, that's currently in phase three with crossover investors TCGX and Goldman Sachs leading the round.

This really brings our third-quarter total to about $6.5 billion.

So that's quite a, a lot considering we're still in August.